Catalyst Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Gyre Therapeutics

31/03/2022 14:31

* Catalyst Biosciences Inc  CBIO.OQ  reported a quarterly
adjusted
loss of 64 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 59 cents per share.
    * Revenue rose 20.1% to $2.44 million from a year ago; 
analysts
expected $166.67 thousand. 
    * Catalyst Biosciences Inc's reported EPS for the quarter
was a
loss of 64 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Catalyst Biosciences Inc shares had fallen by 27.8% this
quarter.
    * The company reported a quarterly loss of $20.33 million.
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 31 at 01:30 p.m.  ​All
figures in US dollars unless otherwise stated